Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Ainsworth

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Inflammatory Bowel Diseases|November 25, 2022
How to Minimize Placebo Response and Remission RatesMark A Ainsworth
Ugeskrift for Laeger|May 22, 2003
[New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role]Mark A Ainsworth
Ugeskrift for Laeger|September 30, 2025
Mark A Ainsworth
Ugeskrift for Laeger|March 16, 2007
[Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis]Mark A Ainsworth, Jørgen Brynskov
Alimentary Pharmacology & Therapeutics|May 5, 2025
Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary GlimpseMark A Ainsworth, Camilla Frimor
Ugeskrift for Laeger|May 25, 2019
[Approval of new medicinal products - administrative procedures]Mark A Ainsworth, Sinan B Sarac
Ugeskrift for Laeger|May 25, 2019
[Approval of new medicinal products - documentation requirements]Mark A Ainsworth, Sinan B Sarac
Ugeskrift for Laeger|September 6, 2005
[Transjugular intrahepatic portosystemic stent-shunts or paracentesis in the treatment of cirrhotic patients with refractory ascites]Mark A Ainsworth, Ole Haagen Nielsen
Ugeskrift for Laeger|July 1, 2005
[Pharmacogenetics--new therapeutic possibilities]Mark A Ainsworth, Ole Haagen Nielsen
The American Journal of Gastroenterology|November 22, 2007
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's diseaseMark A Ainsworth, Klaus Bendtzen, Jørn Brynskov
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Inflammatory Bowel Diseases|November 25, 2022
How to Minimize Placebo Response and Remission RatesMark A Ainsworth
Ugeskrift for Laeger|May 22, 2003
[New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role]Mark A Ainsworth
Ugeskrift for Laeger|September 30, 2025
Mark A Ainsworth
Ugeskrift for Laeger|March 16, 2007
[Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis]Mark A Ainsworth, Jørgen Brynskov
Alimentary Pharmacology & Therapeutics|May 5, 2025
Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary GlimpseMark A Ainsworth, Camilla Frimor
Ugeskrift for Laeger|May 25, 2019
[Approval of new medicinal products - administrative procedures]Mark A Ainsworth, Sinan B Sarac
Ugeskrift for Laeger|May 25, 2019
[Approval of new medicinal products - documentation requirements]Mark A Ainsworth, Sinan B Sarac
Ugeskrift for Laeger|September 6, 2005
[Transjugular intrahepatic portosystemic stent-shunts or paracentesis in the treatment of cirrhotic patients with refractory ascites]Mark A Ainsworth, Ole Haagen Nielsen
Ugeskrift for Laeger|July 1, 2005
[Pharmacogenetics--new therapeutic possibilities]Mark A Ainsworth, Ole Haagen Nielsen
The American Journal of Gastroenterology|November 22, 2007
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's diseaseMark A Ainsworth, Klaus Bendtzen, Jørn Brynskov
Pageof 4